Recombinant HCMV and RHCMV vectors and uses thereof

Patent metadata

Field	Value
Publication number	US-11266732-B2
Application number	US-201815965246-A
Country	US
Kind code	B2
Filing date	Apr 27, 2018
Priority date	May 14, 2010
Publication date	Mar 8, 2022
Grant date	Mar 8, 2022

Abstract

The present disclosure relates to recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens, which may be used, for example, for the treatment or prevention of infectious disease or cancer. The recombinant RhCMV or HCMV vectors elicit and maintain high level cellular immune responses specific for the heterologous antigen while including deletions in one or more genes essential or augmenting for CMV replication, dissemination or spread.

First claim

What is claimed is:

1. A recombinant viral vector comprising a nucleic acid sequence encoding a human cytomegalovirus (HCMV) backbone vector and at least one heterologous antigen, wherein:
(a) the at least one heterologous antigen is a pathogen-specific antigen or a tumor antigen;
(b) the recombinant viral vector comprises a deletion in the HCMV UL115 gene that eliminates expression of a functional gL protein; and
(c) the recombinant viral vector comprises a deletion in the UL128 gene, a deletion in the UL130 gene, a deletion in the UL146 gene, and a deletion in the UL147 gene.

2. The recombinant viral vector of claim 1 , further comprising a deletion in a HCMV gene region selected from the group consisting of: the RL11 family, the pp65 family, the US12 family, and the US28 family.

3. The recombinant viral vector of claim 1 , further comprising a deletion in UL64 or US29, or a combination thereof.

4. The recombinant viral vector of claim 1 , further comprising a deletion in at least one immune modulatory HCMV gene selected from the group consisting of: US2, US3, US4, US5, US6, US7, US8, US9, US10, US11, UL118, UL119, UL36, UL37, and UL111a.

5. The recombinant viral vector of claim 1 , wherein UL122 and/or UL79 are inactivated or deleted.

6. The recombinant viral vector of claim 1 , wherein the heterologous antigen is a herpes simplex virus (HSV)-1 antigen, a HSV-2 antigen, a human papilloma virus (HPV) antigen, a hepatitis B virus antigen, or a prostate cancer antigen.

7. The recombinant viral vector of claim 1 , wherein the heterologous antigen is a Mycobacterium tuberculosis antigen.

8. The recombinant viral vector of claim 1 , wherein the heterologous antigen is Gag, Pol, Env, Rev, Tat, or Nef, or an epitope or antigenic fragment or combination thereof.

9. A method of treating a subject with an infectious disease or cancer comprising administering to the subject in need thereof a recombinant viral vector according to claim 1 .

10. A method of inducing a tumor-specific or pathogen-specific immune response in a subject at risk of developing cancer or becoming infected with an infectious disease comprising administering to the subject in need thereof a recombinant viral vector according to claim 1 .

Assignees

• Univ Oregon Health & Science

Inventors

• Picker Louis
• Nelson Jay A
• Frueh Klaus
• Jarvis Michael A
• Hansen Scott G

Classifications

• A61K39/0011

  Cancer antigens · CPC title

• C12N2710/16111

  Cytomegalovirus, e.g. human herpesvirus 5 · CPC title

• C12N2740/16034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C07K14/005

  from viruses · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title